STOCK TITAN

Aytu BioPharma Inc - AYTU STOCK NEWS

Welcome to our dedicated news page for Aytu BioPharma (Ticker: AYTU), a resource for investors and traders seeking the latest updates and insights on Aytu BioPharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aytu BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aytu BioPharma's position in the market.

Rhea-AI Summary
Aytu BioPharma, Inc. reported Q2 2024 operating income of $2.4 million, net loss of $0.2 million, and adjusted EBITDA of $5.1 million. The Rx Segment net revenue was $18.7 million, with a net income of $0.7 million and adjusted EBITDA of $5.5 million. The ADHD Portfolio net revenue increased by 49% compared to Q2 2023. The company's cash balance was $19.5 million at December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
earnings
-
Rhea-AI Summary
Aytu BioPharma, Inc. (AYTU) will report its financial and operational results for its second quarter of fiscal 2024 on February 14, 2024. The company has scheduled a conference call and webcast to review the results and conduct a question and answer section. Interested parties can access the conference call and webcast through provided call-in and webcast information. A teleconference replay of the call will also be available until February 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
conferences earnings
-
Rhea-AI Summary
Aytu BioPharma, Inc. CEO, Josh Disbrow, will participate in a fireside chat and one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference on February 1, 2024. The webcasted fireside chat will be accessible on the company's website and can be replayed after the event. Management will also engage in virtual one-on-one meetings throughout the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
conferences
Rhea-AI Summary
Aytu BioPharma, Inc. (AYTU) CEO to Participate in Emerging Growth Conference on December 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
conferences acquisition
-
Rhea-AI Summary
Aytu BioPharma, Inc. (NASDAQ:AYTU) announced Q1 2024 financial and operational results, including a net revenue of $22.1 million, a 31% increase in ADHD net revenue, and a $2.2 million Adjusted EBITDA. The company achieved a $20.0 million cash balance and plans to host a conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.11%
Tags
earnings
-
Rhea-AI Summary
Aytu BioPharma, Inc. (NASDAQ:AYTU) ranked 118th on the Deloitte Technology Fast 500 list for 2023, showcasing 11% revenue growth to $107.4 million in fiscal 2023. The company's focus on commercializing novel therapeutics drove a 21% increase in prescription product sales. CEO Josh Disbrow expressed pride in the team's efforts and emphasized the goal of maintaining growth, positive Adjusted EBITDA, net income, and shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
none
Rhea-AI Summary
Aytu BioPharma, Inc. (AYTU) to Report Q1 Fiscal Year 2024 Financial Results on November 14, 2023. Conference call scheduled to review the results. Webcast and replay information provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
conferences earnings
-
Rhea-AI Summary
Aytu BioPharma has received FDA approval for the Prior Approval Supplement (PAS) for Cotempla XR-ODT, enabling the transfer of manufacturing to a third-party manufacturer. This follows a similar achievement for Adzenys XR-ODT. The company expects improved margins for their ADHD products as a result of this manufacturing transfer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
none
-
Rhea-AI Summary
Aytu BioPharma to present at Lytham Partners Fall 2023 Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.59%
Tags
conferences
Rhea-AI Summary
Aytu BioPharma reports Q4 2023 net revenue of $30.7 million, a 12% increase YoY, and adjusted EBITDA of $7.7 million. Q4 2023 total prescriptions increased 32% YoY. Rx segment net revenue was $23.3 million with adjusted EBITDA of $8.3 million. Consumer Health revenue decreased 15% YoY. Gross margins improved to 60% in Q4 2023. Net loss was $2.5 million in Q4 2023. Cash and cash equivalents were $23.0 million at June 30, 2023. FY 2023 net revenue was $107.4 million, an 11% increase YoY. Rx segment net revenue was $73.8 million. ADHD products net revenue increased 9% YoY. Pediatric products net revenue increased 58% YoY. Consumer Health revenue decreased 5% YoY. Gross margins improved to 62% in FY 2023. Net loss was $17.1 million in FY 2023. Total adjusted EBITDA was positive $3.2 million in FY 2023. Aytu plans to de-emphasize and monetize the Consumer Health segment. Management expects continued growth in the Rx segment and aims for consistent profitability and positive cash flow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.48%
Tags
earnings
Aytu BioPharma Inc

Nasdaq:AYTU

AYTU Rankings

AYTU Stock Data

17.15M
3.80M
3.48%
31.78%
6.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Loveland

About AYTU

aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.